SEC Form 4 · accession 0000880771-17-000008
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Jan 20, 2017
Accepted (ET)
Jan 24, 2017 · 7:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 20, 2017 | M | 12,400 | $1.81 | A | 99,184 | D | |
| Common Stock | Jan 20, 2017 | S | 12,400 | $10.3823 | D | 86,784 | D | |
| Common Stock | Jan 23, 2017 | M | 18,000 | $1.81 | A | 104,784 | D | |
| Common Stock | Jan 23, 2017 | S | 18,000 | $10.4138 | D | 86,784 | D | |
| Common Stock | Jan 23, 2017 | M | 4,807 | $1.08 | A | 91,591 | D | |
| Common Stock | Jan 23, 2017 | S | 4,807 | $10.4138 | D | 86,784 | D | |
| Common Stock | Jan 24, 2017 | M | 21,132 | $1.08 | A | 107,916 | D | |
| Common Stock | Jan 24, 2017 | S | 21,132 | $10.5101 | D | 86,784 | D | |
| Common Stock | Jan 24, 2017 | M | 4,793 | $1.08 | A | 91,577 | D | |
| Common Stock | Jan 24, 2017 | S | 4,793 | $10.4082 | D | 86,784 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionsF2,F3 | $1.81 | Jan 20, 2017 | M | 12,400 | D | — | Mar 18, 2018 | Common Stock | 12,400 | 18,000 | D |
| Non-Qualified Stock OptionsF2,F3 | $1.81 | Jan 23, 2017 | M | 18,000 | D | — | Mar 18, 2018 | Common Stock | 18,000 | 0 | D |
| Non-Qualified Stock OptionsF2,F4 | $1.08 | Jan 23, 2017 | M | 4,807 | D | — | Mar 6, 2019 | Common Stock | 4,807 | 95,193 | D |
| Non-Qualified Stock OptionsF2,F4 | $1.08 | Jan 24, 2017 | M | 21,132 | D | — | Mar 6, 2019 | Common Stock | 21,132 | 74,061 | D |
| Non-Qualified Stock OptionsF2,F4 | $1.08 | Jan 24, 2017 | M | 4,793 | D | — | Mar 6, 2019 | Common Stock | 4,793 | 69,268 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F31/36th of such shares will vest on June 1, 2010 and 1/36th will vest monthly thereafter over a three-year period, provided the reporting person remains employed by the Company.
- F425% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.